A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium
ConditionCytomegalovirus (CMV)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorTakeda
About this trial
Cytomegalovirus (CMV) is a common virus that infects many people. It can cause serious illness in people with weak immune systems especially in those undergoing transplants. Maribavir is a medicine approved for treating CMV infection in adults after transplant.
The main aim of this study is to check the use of maribavir and learn how safe and effective in treating adults with CMV infection after transplant in Belgium in line with the Belgian reimbursement criteria.
During the study, a participant's data will be collected for 2 years. The study does not have fixed visits to the hospital, but it is recommended collect data from routine visits and contacts.
Eligibility criteria
Qualifiers
Participant signed an informed consent form.
Aged greater than or equal to (>=) 18 years at the time of consent.
Received an HSCT/SOT.
Diagnosed with CMV infection/disease any time after the HSCT/SOT date.
Disqualifiers
None
Trial design
Treatments tested in this trial
- No Intervention
Treatment groups
75 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov